inflammatory bowel disease, myositis, psoriatric arthritis, Reumatoid Arthritis, SLE
Conditions
Brief summary
The primary endpoint is the concentration of prednisolone in the breastfeeding child’s plasma 2 hr after feeding an infant breast milk, with the feeding taking place at 1 hr following maternal dose intake.
Detailed description
Concentration of prednisolone and prednisone in breast milk at 1h after maternal dose intake and the maternal plasma concentration of prednisolone and prednisone at 1h after prednisolone intake., Concentration of cortisol in the infant blood at same timepoint blood is drawn for PK measurement.
Interventions
DRUGPREDNISOLONE
Sponsors
Uppsala Universitet
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the concentration of prednisolone in the breastfeeding child’s plasma 2 hr after feeding an infant breast milk, with the feeding taking place at 1 hr following maternal dose intake. | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of prednisolone and prednisone in breast milk at 1h after maternal dose intake and the maternal plasma concentration of prednisolone and prednisone at 1h after prednisolone intake., Concentration of cortisol in the infant blood at same timepoint blood is drawn for PK measurement. | — |
Countries
Sweden
Outcome results
None listed